How ethics review works for clinical trials in China
An ethics committee in China must review a study and give its opinion within 30 days of accepting the application.1 Every drug trial and every device trial needs that opinion before it starts.23 In a trial at more than one site, the lead institution and each participating institution all organise review, and a participating site may confirm the lead committee’s opinion by a simplified procedure.1
A reader who knows single-IRB review in the United States, or the single opinion per Member State under the EU rules, will look for one committee that binds every site. The Chinese measures provide for cooperation between committees. Each institution still acts, and under the device rules a participating site keeps the right to refuse the trial at its own institution.4
The instrument
The Measures for the Ethical Review of Life Science and Medical Research Involving Humans were issued on 18 February 2023 as document Guo Wei Ke Jiao Fa [2023] No. 4, and took effect on issue.1 Four bodies issued them: the National Health Commission, the Ministry of Education, the Ministry of Science and Technology and the National Administration of Traditional Chinese Medicine.1
Article 2 applies the Measures to ethics review at medical and health institutions, institutions of higher education, research institutes and similar bodies in China.1 Article 3 covers research that uses people as subjects, and research that uses human biological samples or information data. Health records and behavioural data are named as information data.1
Who must have a committee
Article 5 names the institutions that bear responsibility for ethics review and must set up a committee.1
- medical institutions at the second grade or above
- health institutions at the level of a city divided into districts or above
- institutions of higher education
- research institutes
Article 14 deals with an institution that has no committee, or whose committee is unable to review the study. It may entrust the review in writing to a capable institutional committee or to a regional ethics committee.1 The entrusted committee carries out the continuing review as well. A medical institution must entrust a committee at an institution of its own grade or higher, or a regional committee.1
The period for review
Article 15 makes review at a meeting of the committee the usual form.1 Article 16 requires the committee to carry out the review and issue its opinion within 30 days of acceptance.1 Urgent cases are reviewed promptly. In an emergency such as an outbreak of disease, the review is generally carried out and the opinion issued within 72 hours, and the requirements and quality of the review may not be lowered.1
The Measures state the period in days. The drug and device registration measures count their periods in working days, and the two should be read separately.25
What the committee reviews against
Article 17 requires research to have scientific and social value and sets six basic requirements.1
- control of risk, with a reasonable ratio of risk to benefit and the risk to participants kept to a minimum
- informed consent, with a right to withdraw unconditionally at any stage
- fairness in selecting participants and in sharing benefits, risks and burdens
- no charge to participants, with compensation for reasonable expenses and free treatment for research-related harm
- protection of privacy and personal information
- special protection for particular groups, such as children, pregnant women and people with intellectual or mental disabilities
Deception, inducement and coercion to obtain consent are prohibited.1 Personal information may be disclosed to a third party only with the participant’s authorisation.1
Trials at more than one site
Article 27 allows institutions running the same study to set up a cooperation mechanism for ethics review, so that they act consistently and in good time.1 The lead institution and the participating institutions must all organise review. The committee of each participating institution carries out the continuing review of the research at its own institution.1
Article 31 lists the cases in which a simplified procedure is available.1
- research whose risk is no greater than minimal risk
- a minor amendment to an approved protocol that leaves the ratio of risk to benefit unchanged
- continuing review of approved research
- confirmation by a participating institution’s committee of the opinion issued by the lead institution’s committee
Under the simplified procedure the chair of the committee designates two or more members to review and to issue the opinion, which is reported at a meeting of the committee.1 The review moves to a meeting where the ratio of risk to benefit changes, where the reviewing members disagree, or where a member asks for it.1
The good clinical practice for device trials adds a rule for multi-centre device trials. Once the committee of the lead institution has passed the ethics and the science of the protocol, the committees of the other institutions generally propose no changes to its design. They keep the right to refuse the trial at their own institution.4
Review after approval
Article 25 requires the researcher to submit reports on the following.1
- progress of the research
- serious adverse events
- deviations from the protocol
- suspension
- termination
- completion of the research
The committee carries out continuing review on those reports, and the interval between continuing reviews may be no longer than 12 months.1 Article 26 requires the researcher to report a serious adverse event to the committee immediately. The committee then reviews whether the protective measures are sufficient, reassesses the ratio of risk to benefit and issues an opinion.1
The device rules set their own clock for the investigator, who reports a serious adverse event to the ethics committee within 24 hours of learning of it.4 A revised protocol or informed consent form, and the resumption of a suspended device trial, need fresh written consent from the committee.4
Research that may be exempt
Article 32 allows exemption from ethics review for certain research on human information data or biological samples. The research must cause no harm to the human body and must involve no sensitive personal information and no commercial interest.1 Four kinds of research are named.1
- research on lawfully obtained public data, or on data from observation that does not interfere with public behaviour
- research on anonymised information data
- research on existing human biological samples, within the scope of the informed consent and from a lawful and ethical source
- research on human cell lines from a biobank, within the scope authorised by the provider
The third and fourth kinds exclude work on human germ cells or embryos, reproductive cloning, chimeras and heritable gene manipulation.1
Questions people also ask
How long does ethics review take in China?
The committee must carry out the review and issue its opinion within 30 days of accepting the application.1 In an emergency such as an outbreak the period is generally 72 hours.1
Does China have a single ethics review for multi-centre trials?
The lead institution and the participating institutions must all organise ethics review.1 A participating committee may confirm the lead committee’s opinion by the simplified procedure.1
How often must an approved study be reviewed again?
The interval between continuing reviews may be no longer than 12 months.1
Can an institution without its own committee run a study?
Such an institution may entrust the review in writing to a capable institutional committee or to a regional ethics committee.1
Is research on anonymised data exempt from ethics review?
Article 32 names research on anonymised information data among the kinds that may be exempt, where the research causes no harm and involves no sensitive personal information and no commercial interest.1
Footnotes
-
Measures for the Ethical Review of Life Science and Medical Research Involving Humans, Guo Wei Ke Jiao Fa [2023] No. 4, Articles 2, 3, 5, 14 to 17, 25 to 27, 31, 32 and 54. https://www.gov.cn/zhengce/zhengceku/2023-02/28/content_5743658.htm ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24 ↩25 ↩26 ↩27 ↩28 ↩29 ↩30 ↩31 ↩32 ↩33
-
Drug Administration Law of the People’s Republic of China (revised 2019), Article 20, and Measures for the Administration of Drug Registration (State Administration for Market Regulation Order No. 27), Articles 25 and 125. ↩ ↩2
-
Regulations on the Supervision and Administration of Medical Devices (State Council Order No. 739), Article 28. https://www.gov.cn/zhengce/content/2021-03/18/content_5593739.htm ↩
-
Good Clinical Practice for Medical Device Clinical Trials, in force from 1 May 2022, Articles 16, 32 and 55. https://yjj.scjgj.fujian.gov.cn/ylqx/flfg/202204/t20220406_5875596.htm ↩ ↩2 ↩3 ↩4
-
Measures for the Registration and Filing of Medical Devices (State Administration for Market Regulation Order No. 47), Article 99. ↩
Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.